Medtronic Inc. said Tuesday that regulators in the European Union have approved the latest version of its CoreValve heart system.
The CoreValve delivery system is designed to help surgeons replace a diseased aortic valve without taking out the original valve and without open heart surgery. Instead, they put a new valve into a catheter and guide the catheter to the heart from an artery in the leg.
The CoreValve system was first approved in Europe in March 2007, but is not yet approved in the U.S.
The newest version of the system includes AccuTrak technology, which Medtronic said will give surgeons greater control during implant procedures.
Medtronic is the world's biggest medical device company by revenue. In midday trading its shares lost 32 cents to $32.66.